Images List Premium Download Classic

Immunogenic

Immunogenic-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Method for decreasing immunogenicity
Esbatech, An Alcon Biomedical Research Unit Llc
January 18, 2018 - N°20180016350

A method for decreasing the immunogenicity of antibody variable domains is disclosed.
NEW Stable, spray dryed, immunogenic, viral compositions
Aeras
January 18, 2018 - N°20180015158

Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, mva viruses, and baculoviruses which encode one or more antigens of interest, such as tb, malarial, and hiv antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (mctd) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, ...
Universal killer t-cell
Oslo Universitetssykehus Hf
January 11, 2018 - N°20180010097

The present invention relates to a modified natural killer (nk) cell and its use in personalised medicine. The modified nk cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic ...
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells
Imnate Sarl
January 11, 2018 - N°20180009843

The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.
Vaccines for porcine epidemic diarrhea virus infections
Kansas State University Research Foundation
January 11, 2018 - N°20180008699

Isolated porcine epidemic diarrhea virus (pedv) deposited under atcc accession no. Pta-121847, and attenuated strains generated by serial passage in culture of the deposited strain. Immunogenic compositions for reducing the incidence or severity of clinical symptoms from pedv infection, and methods of making and using the same.
Rna virus attenuation by alteration of mutational robustness and sequence space
Institut Pasteur
January 11, 2018 - N°20180008689

The application generally relates to the attenuation of a rna virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said rna virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious rna virus or clone, for the production of immunogenic ...
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel 3' end caps, 5' end caps and combinations thereof for therapeutic rna
Novartis Ag
January 04, 2018 - N°20180002368

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
Simian adenovirus and hybrid adenoviral vectors
Oxford University Innovation Limited
January 04, 2018 - N°20180000966

Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus ady25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.
Immunogenicity of an optimized synthetic consensus dna vaccine for porcine epidemic diarrhea virus
The Trustees Of The University Of Pennsylvania
January 04, 2018 - N°20180000928

Provided herein is a vaccine comprising a porcine epidemic diarrhea virus (pedv) antigen. The antigen can be a consensus antigen. Also disclosed herein is a method of treating a porcine in need thereof, by administering the vaccine to the porcine.
Immunogenic compositions for use in pneumococcal vaccines
Pfizer Inc.
January 04, 2018 - N°20180000922

An object of the present invention is to provide immunogenic compositions for protection against s. Pneumoniae, in particular against s. Pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
Modifying macrophage phenotype for treatment of disease
Apellis Pharmaceuticals, Inc.
January 04, 2018 - N°20180000899

The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e. G., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple ...
High molecular weight polysaccharide that binds and inhibits virus
World Force Technologies, Llc
January 04, 2018 - N°20180000882

This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/...
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
The United States Of America, As Represented By The Secretary, Department Of Health And Human
December 28, 2017 - N°20170369535

The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of ...
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for inhibiting polyomavirus-associated pathology
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
December 28, 2017 - N°20170368163

Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, bkv serotype i (bkv-i), bkv serotype ii (bkv-ii), bkv serotype iii (bkv-iii) and/or bkv serotype iv (bkv-iv)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, bkv-associated hemorrhagic cystitis, or jc virus-associated progressive multifocal leukoencephalopathy; pml). Further disclosed are immunogenic compositions of ...
Toxoid preparation and uses thereof
Arytha Biosciences, Llc
December 28, 2017 - N°20170368160

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions ...
Peptides, devices, and methods for the detection of anaplasma antibodies
Abaxis, Inc.
December 21, 2017 - N°20170363639

The invention provides populations of isolated peptides useful for the detection of antibodies that bind to anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the anaplasma outer membrane protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to anaplasma antigens and ...
Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital
December 21, 2017 - N°20170362337

Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating globo-h-positive cancer.
Hiv vaccine formulation
Janssen Vaccines & Prevention B.v.
December 21, 2017 - N°20170362280

Immunogenic compositions containing a human immunodeficiency virus (hiv) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an hiv in ...
Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
Sanofi Pasteur
December 21, 2017 - N°20170360923

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, ...
Vaccine against infectious bronchitis virus
Boehringer Ingelheim Vetmedica Gmbh
December 21, 2017 - N°20170360921

Embodiments of the present invention relate to an infectious bronchitis virus (ibv) and an immunogenic composition comprising an ibv, respectively, wherein the orf 3a and/or the orf 3b and/or the orf 5a and/or the orf 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the ...
Novel tilapia virus and uses thereof
Kimron Veterinary Institute
December 21, 2017 - N°20170360918

The invention is directed to isolated tilapia lake virus or tilv, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from tilv, and use of these reagents for detecting the presence or absence of tilv in an animal. The invention also relates to irnas which target nucleic acid ...
Loading